CO2021014899A2 - Formulación para entrega oral de proteinas, peptidos y moleculas pequeñas con permeabilidad baja - Google Patents

Formulación para entrega oral de proteinas, peptidos y moleculas pequeñas con permeabilidad baja

Info

Publication number
CO2021014899A2
CO2021014899A2 CONC2021/0014899A CO2021014899A CO2021014899A2 CO 2021014899 A2 CO2021014899 A2 CO 2021014899A2 CO 2021014899 A CO2021014899 A CO 2021014899A CO 2021014899 A2 CO2021014899 A2 CO 2021014899A2
Authority
CO
Colombia
Prior art keywords
formulation
weight
oral delivery
amount
peptides
Prior art date
Application number
CONC2021/0014899A
Other languages
English (en)
Inventor
Vincent Plassat
Benoit Hilbold
Aurélia Galus
Thomas Pointeaux
Julien Meissonnier
Gene M Dubowchik
Charles M Conway
Original Assignee
Scherer Technologies Llc R P
Biohaven Pharm Holding Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Scherer Technologies Llc R P, Biohaven Pharm Holding Co Ltd filed Critical Scherer Technologies Llc R P
Publication of CO2021014899A2 publication Critical patent/CO2021014899A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/03—Peptides having up to 20 amino acids in an undefined or only partially defined sequence; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans

Abstract

La presente divulgación está dirigida a una formulación farmacéutica destinada para la entrega oral de inhibidores de péptido relacionado con gen de calcitonina (CGRP) sintéticos o naturales poco permeables o sales/solvatos de éstos que tienen una actividad terapéutica. La formulación farmacéutica puede incluir un inhibidor de CGRP sintético o natural poco permeable o sal o solvato de éste en una cantidad de 0.01 a 10% en peso del peso total de la formulación; una fase lipofílica que comprende triglicéridos de ácidos grasos en una cantidad de 50 a 80% en peso del peso total de la formulación; y por lo menos un tensoactivo lipofílico que comprende ésteres parciales de poliol y ácidos grasos en una cantidad de aproximadamente 10 a 50% en peso del peso total de la formulación
CONC2021/0014899A 2019-04-11 2021-11-04 Formulación para entrega oral de proteinas, peptidos y moleculas pequeñas con permeabilidad baja CO2021014899A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962832508P 2019-04-11 2019-04-11
PCT/US2020/027800 WO2020210722A1 (en) 2019-04-11 2020-04-10 Formulation for oral delivery of proteins, peptides and small molecules with poor permeability

Publications (1)

Publication Number Publication Date
CO2021014899A2 true CO2021014899A2 (es) 2021-11-19

Family

ID=70476554

Family Applications (2)

Application Number Title Priority Date Filing Date
CONC2021/0012462A CO2021012462A2 (es) 2019-04-11 2021-09-23 Formulación para entrega oral de proteinas, peptidos y moleculas pequeñas con permeabilidad baja
CONC2021/0014899A CO2021014899A2 (es) 2019-04-11 2021-11-04 Formulación para entrega oral de proteinas, peptidos y moleculas pequeñas con permeabilidad baja

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CONC2021/0012462A CO2021012462A2 (es) 2019-04-11 2021-09-23 Formulación para entrega oral de proteinas, peptidos y moleculas pequeñas con permeabilidad baja

Country Status (16)

Country Link
US (3) US11185589B2 (es)
EP (2) EP3952900A1 (es)
JP (2) JP2022526833A (es)
KR (2) KR20210151187A (es)
CN (2) CN113966223A (es)
AR (1) AR118654A1 (es)
AU (2) AU2020270985A1 (es)
BR (2) BR112021020287A2 (es)
CA (2) CA3134550A1 (es)
CO (2) CO2021012462A2 (es)
EA (2) EA202192793A1 (es)
IL (2) IL287084A (es)
MX (2) MX2021012354A (es)
SG (2) SG11202110546UA (es)
WO (2) WO2020210722A1 (es)
ZA (1) ZA202108909B (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116456981A (zh) * 2020-11-19 2023-07-18 辉瑞爱尔兰制药公司 用于改善的grp抑制剂递送的组合物

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8903804D0 (en) * 1989-02-20 1989-04-05 Sandoz Ltd Improvements in or relating to organic compounds
JPH08507078A (ja) * 1993-02-17 1996-07-30 スミスクライン・ビーチャム・コーポレイション 治療用ペプチド含有のミクロエマルジョン
GB9405304D0 (en) * 1994-03-16 1994-04-27 Scherer Ltd R P Delivery systems for hydrophobic drugs
US6761903B2 (en) * 1999-06-30 2004-07-13 Lipocine, Inc. Clear oil-containing pharmaceutical compositions containing a therapeutic agent
FR2803203B1 (fr) * 1999-12-31 2002-05-10 Fournier Ind & Sante Nouvelles formulations galeniques du fenofibrate
SK10722003A3 (sk) 2001-02-27 2004-02-03 Astrazeneca Ab Farmaceutická formulácia obsahujúca bicalutamid v pevnej disperzii s enterickým polymérom a jej použitie
IL158765A0 (en) * 2001-06-21 2004-05-12 Pfizer Prod Inc Self-emulsifying formulations of cholesteryl ester transfer protein inhibitors
EP1460992B1 (en) * 2001-12-03 2009-03-11 Dor Biopharma, Inc. Stabilized reverse micelle compositions and uses thereof
KR20120004541A (ko) 2002-06-05 2012-01-12 브리스톨-마이어스 스큅 컴퍼니 칼시토닌 유전자 관련 펩티드 수용체 길항제
US20050249802A1 (en) 2004-05-06 2005-11-10 The Procter & Gamble Company Softgel encapsulated pharmaceutical compositions comprising concentrated active ingredients
CN101048137A (zh) * 2004-10-29 2007-10-03 诺瓦提斯公司 可自发分散的药物组合物
KR20070084531A (ko) * 2004-11-24 2007-08-24 머크 앤드 캄파니 인코포레이티드 치환된 아미드의 경구 투여용 액체 및 반고체 약제학적제형
US20080014274A1 (en) 2006-07-14 2008-01-17 Wyeth Enhanced stability phenylephrine liquid compositions
CN101511184A (zh) * 2006-09-08 2009-08-19 默克公司 用于口服给药cgrp拮抗剂的液体药物制剂
EP2157967B1 (en) * 2007-04-23 2013-01-16 Intarcia Therapeutics, Inc Suspension formulations of insulinotropic peptides and uses thereof
US8323695B2 (en) 2007-08-13 2012-12-04 Mcneil-Ppc, Inc. Method for stabilizing phenylephrine
CA2699065A1 (en) * 2007-09-11 2009-04-02 Mondobiotech Laboratories Ag Use of a peptide as a therapeutic agent
IL188647A0 (en) * 2008-01-08 2008-11-03 Orina Gribova Adaptable structured drug and supplements administration system (for oral and/or transdermal applications)
AU2010332797B2 (en) 2009-12-18 2015-05-28 Catalent Pharma Solutions Gmbh Pharmaceutical oral dosage form containing a synthetic oligosaccharide
US8481546B2 (en) 2010-03-30 2013-07-09 Bristol-Myers Squibb Company CGRP receptor antagonist
SG11201407512VA (en) * 2012-05-18 2014-12-30 Genentech Inc High-concentration monoclonal antibody formulations
PL2961377T3 (pl) 2013-02-28 2020-11-02 Pf Consumer Healthcare 1 Llc Zwiększona stabilność nowych ciekłych kompozycji
US8859623B1 (en) 2013-11-14 2014-10-14 Paragon BioTeck, Inc. Methods and compositions of stable phenylephrine formulations
JP2017515852A (ja) * 2014-05-16 2017-06-15 ソーク インスティテュート フォー バイオロジカル スタディーズ 代謝障害を処置するための組成物および方法
WO2017062997A1 (en) 2015-10-09 2017-04-13 Reckitt Benckiser Llc Pharmaceutical formulation
EP3362048A4 (en) * 2015-10-14 2019-06-05 Pharcon Inc. COMPOSITION FOR INTRAORAL ADMINISTRATION OF PEPTIDES AND BIOLOGICALLY ACTIVE PROTEINS

Also Published As

Publication number Publication date
CN113966223A (zh) 2022-01-21
KR20210151185A (ko) 2021-12-13
EA202192793A1 (ru) 2022-01-12
AU2020270985A1 (en) 2021-12-09
TW202103726A (zh) 2021-02-01
EP3952900A1 (en) 2022-02-16
AR118654A1 (es) 2021-10-20
BR112021020287A2 (pt) 2021-12-14
CA3136485A1 (en) 2020-10-15
US20220143188A1 (en) 2022-05-12
US20200323985A1 (en) 2020-10-15
WO2020210722A1 (en) 2020-10-15
US20220249468A1 (en) 2022-08-11
CO2021012462A2 (es) 2021-09-30
JP2022526833A (ja) 2022-05-26
IL287084A (en) 2021-12-01
SG11202110546UA (en) 2021-10-28
AU2020272059A1 (en) 2021-12-09
EA202192792A1 (ru) 2022-01-11
CA3134550A1 (en) 2020-10-15
US11185589B2 (en) 2021-11-30
CN113784722A (zh) 2021-12-10
JP2022526196A (ja) 2022-05-23
IL287131A (en) 2021-12-01
EP3952899A1 (en) 2022-02-16
SG11202111251SA (en) 2021-11-29
MX2021012354A (es) 2021-10-22
BR112021018817A2 (pt) 2021-11-23
MX2021012356A (es) 2021-11-04
KR20210151187A (ko) 2021-12-13
ZA202108909B (en) 2022-07-27
WO2020210723A1 (en) 2020-10-15

Similar Documents

Publication Publication Date Title
ES2539861T3 (es) Formulaciones en emulsión de clevidipina que contienen agentes antimicrobianos
ES2524320T3 (es) Composición para la prevención o el tratamiento de enfermedad asociada con trombo o émbolo
US11744853B2 (en) Method of administration and treatment
SV2019005808A (es) Nuevos analógos de urocortina - 2 modificados con ácido graso para el tratamiento de diabetes y enfermedad renal cronica
Perry et al. Neurochemical and behavioral profiling of the selective GlyT1 inhibitors ALX5407 and LY2365109 indicate a preferential action in caudal vs. cortical brain areas
CO6290632A2 (es) Composición oral que contiene péptidos y proteasas
AR077484A1 (es) Formulacion de acetato de glatiramer de volumen reducido y metodos para su administracion
Huhn et al. Age-related loss of cardiac preconditioning: impact of protein kinase A
CO2021014899A2 (es) Formulación para entrega oral de proteinas, peptidos y moleculas pequeñas con permeabilidad baja
BR112014029245A2 (pt) métodos para diminuir a proteína convertase subtilisina/quexina tipo 9 (pcsk9)
AR038385A1 (es) Formas de dosificacion farmaceutica de liberacion controlada de un inhibidor de la proteina de transferencia de ester de colesterilo
RU2017112149A (ru) Комбинация омега-3 жирной кислоты и SGLT-2 ингибитора для лечения болезней печени
BR112013019513A2 (pt) métodos para o tratamento de úlceras diabéticas do pé
AR114324A1 (es) Péptidos de la cadena b de la relaxina lipidados modificados y su uso terapéutico
UY38069A (es) Péptidos de la cadena b de la relaxina lipidados modificados y su uso terapéutico
CO2021011652A2 (es) Ésteres de ácido graso como agentes anti-malassezia
UY38067A (es) Péptidos de la cadena b de la relaxina modificados y su uso terapéutico
CO2022005904A2 (es) Composiciones sólidas que comprenden un inhibidor de pcsk9 y una sal de ácido n-(8-(2-hidroxibenzoil)amino)caprílico
CO2022000575A2 (es) Composiciones sólidas que comprenden un derivado de egf(a) y una sal de ácido n-(8-(2-hidroxibenzoil)amino)caprílico
BR112015014261A8 (pt) composto de danazol, seu uso e formulação farmacêutica compreendendo este
UY31826A (es) Compuesto peptídico y su uso
RU2019134554A (ru) Липосомальные композиции и содержащие их твердые пероральные лекарственные формы
CL2021000627A1 (es) Composiciones farmacéuticas adecuadas para liberación articular y su uso en el tratamiento del dolor articular
Ai et al. Disruption of Cdk5-GluN2B complex by a small interfering peptide attenuates social isolation-induced escalated intermale attack behavior and hippocampal oxidative stress in mice
CL2023001739A1 (es) Ésteres de ácidos dicarboxílicos para el tratamiento de enfermedades y padecimientos asociados con la toxina